Canadian start-up’s self-assembling scaffold creates high avidity antibodies against challenging targets

How one trial plus confirmatory evidence can add up to approval

Ten companies you may not have heard of tackling checkpoint resistance at AACR22

NIAID’s Fauci in conversation: what the NIAID director thinks will move the needle in vaccine design